Hemispherx (HEB) fails to win FDA panel backing for Ampligen efficacy
Tweet
Share
E-mailGet Alerts HEB Hot Sheet
Join SI Premium – FREE
Hemispherx Biopharma, Inc. (NYSE: HEB) fails to win FDA panel backing for Ampligen efficacy.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Reddit (RDDT) added to S&P 500
- Jane Street Took $15 Billion Hit In July Tied To Situational Awareness - Reuters
- Avalonbay Communities (AVB) dropped from S&P 500
Create E-mail Alert Related Categories
FDA, Trader TalkSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
